RBC Capital lowered the firm’s price target on Intellia Therapeutics (NTLA) to $9 from $14 and keeps a Sector Perform rating on the shares. The company’s Q3 report include the death of the Hy’s Law case patient, which makes it “difficult to see a path forward” for the program and the risk/benefit profile tilts unfavorably, especially for an indication where there are safer therapeutic alternatives, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $27 from $33 at Oppenheimer
- Intellia: Patient who experienced Grade 4 liver safety event has passed away
- Intellia Therapeutics reports Q3 EPS (92c) vs. ($1.34) last year
- Intellia Therapeutics price target lowered to $4 from $9 at Baird
- Intellia Therapeutics: Hold Rating Amid Safety Concerns and Regulatory Challenges